Join the RSV Vaccine Pref3, Recombinant group to help and get support from people like you.
RSV Vaccine Pref3, Recombinant News (Page 2)
RSV Vaccination Prevents Associated Hospitalization, Emergency Encounters
THURSDAY, Nov. 7, 2024 – For adults aged 60 years or older, respiratory syncytial virus (RSV) vaccination is effective for preventing associated hospitalizations and emergency department encounters,...
IDSA: Vaccination Less Likely With Increasing Social Vulnerability, Black Race
FRIDAY, Oct. 18, 2024 – Vaccination for influenza, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and respiratory syncytial virus (RSV) is less likely with an increasing social...
Poll Finds Public Fears Over RSV Have Eased, Although It Remains a Threat
WEDNESDAY, Oct. 16, 2024 – Public concerns about contracting RSV (respiratory syncytial virus) have significantly declined during the past year, a new survey shows. About 1 in 4 people (26%) are now...
FDA Approves Expanded Age Indication for GSK’s Arexvy, the First Respiratory Syncytial Virus (RSV) Vaccine for Adults Aged 50-59 at Increased Risk
Philadelphia, PA June 07 2024 – GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for...